Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
39.42
-0.81 (-2.01%)
At close: Sep 11, 2025, 4:00 PM EDT
38.64
-0.78 (-1.98%)
After-hours: Sep 11, 2025, 7:22 PM EDT
PRAX Revenue
Praxis Precision Medicines had revenue of $7.77M in the twelve months ending June 30, 2025, up 338.45% year-over-year. In the year 2024, Praxis Precision Medicines had annual revenue of $8.55M with 249.53% growth.
Revenue (ttm)
$7.77M
Revenue Growth
+338.45%
P/S Ratio
103.35
Revenue / Employee
$66,940
Employees
116
Market Cap
829.77M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.55M | 6.11M | 249.53% |
Dec 31, 2023 | 2.45M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PRAX News
- 7 days ago - Praxis Precision Medicines to Participate in September Investor Conferences - GlobeNewsWire
- 8 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Praxis Precision Medicines to Participate in Upcoming Fireside Chat - GlobeNewsWire
- 17 days ago - Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline - GlobeNewsWire
- 4 weeks ago - PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 5 weeks ago - Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewsWire
- 5 weeks ago - Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire